Case Report
Prolonged Use of Dexmedetomidine Infusion in an Infant for Sedation as Adjuvant Therapy
Paola Genovese1*, Joseph Tobias1 and Anjana Kundu21Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA
2Department of Anesthesiology, Dayton Children's Hospital, Ohio, USA
- *Corresponding Author:
- Paola Genovese
Department of Anesthesiology and Pain Medicine
Nationwide Children's Hospital, Columbus, Ohio, USA
Tel: (614) 722-4200
Fax: (614) 722-4203
E-mail: paogenovese@gmail.com
Received date: December 08, 2016; Accepted date: September 11, 2017; Published date: September 16, 2017
Citation: Genovese P, Tobias J, Kundu A (2017) Prolonged Use of Dexmedetomidine Infusion in an Infant for Sedation as Adjuvant Therapy. J Palliat Care Med 7:319. doi:10.4172/2165-7386.1000319
Copyright: © 2017 Genovese P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Dexmedetomidine, a central and peripheral alpha-2 receptor agonist approved by the FDA for the use in patients 18 years old and older, it has been increasingly used in the pediatric population for sedation and analgesia due to its advantage of minimal respiratory depression and lack of abuse/dependence. This is a case report of a successful use of dexmedetomidine in an infant for 15 weeks achieving; symptom control, reduction in the dose of opioids and benzodiazepines by 50% and a safe transition to oral equivalents.
